AULOS BIOSCIENCE
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. Their initial clinical candidate, AU-007, stands apart from existing IL-2 therapeutics by introducing a novel approach that addresses a significant medical challenge of the present era: the eradication of cancer. Through harnessing the anti-cancer potential of interleukin-2, they are breaking down barriers in the field of immuno-oncology. Their distinctive immunotherapy, computationally designed to precisely guide the immune system in attacking tumor cells, is poised to make a substantial impact.
AULOS BIOSCIENCE
Social Links:
Industry:
Biotechnology Health Care Life Science Medical Oncology Therapeutics
Founded:
2020-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.aulosbio.com
Total Employee:
11+
Status:
Active
Contact:
(617) 294-6790
Total Funding:
60 M USD
Technology used in webpage:
Euro Amazon 123FormBuilder
Similar Organizations
Actym Therapeutics, Inc.
Actym Therapeutics is a biotech company that focuses on the discovery and development of novel immuno-oncology therapies to treat cancer.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Immunitas Therapeutics
Immunitas Therapeutics is a single cell genomics-based drug discovery company that modulates oncology targets.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Medicenna Therapeutics
Medicenna is a clinical stage, privately held, immuno-oncology company.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
Apple Tree Partners
Apple Tree Partners investment in Series A - Aulos Bioscience
Apple Tree Partners
Apple Tree Partners investment in Series A - Aulos Bioscience
Official Site Inspections
http://www.aulosbio.com
- Host name: ec2-3-128-232-116.us-east-2.compute.amazonaws.com
- IP address: 3.128.232.116
- Location: Columbus United States
- Latitude: 39.9653
- Longitude: -83.0235
- Metro Code: 535
- Timezone: America/New_York
- Postal: 43215
More informations about "Aulos Bioscience"
Our Leadership Team - Aulos Bioscience
Our leadership team has a proven track record in the discovery, development and commercialization of groundbreaking monoclonal antibody, oncology and immunology …See details»
About Us - Changemakers in the immuno-oncology - Aulos …
Changemaker status in the immuno-oncology field. Our initial clinical candidate, AU-007, stands distinctly separate from all other current IL-2 therapeutics with a novel approach that we …See details»
Aulos Bioscience - Crunchbase Company Profile & Funding
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. Their initial clinical candidate, AU-007, stands apart from …See details»
Aulos Bioscience - LinkedIn
Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune ...See details»
ATP and Biolojic Design Launch Aulos Bioscience to Develop …
Jan 8, 2021 A link to the webcast will be available on the Aulos website at aulosbio.com. About ATP. Founded in 1999, ATP is a leader in life sciences venture capital, ...See details»
Mace Rothenberg, M.D., Joins Aulos Bioscience Board of Directors
Mar 30, 2021 Over a 10-year period, his organization developed and obtained regulatory approvals for 11 new cancer medicines, including IBRANCE® (palbociclib), the first CDK 4/6 …See details»
Aulos Bioscience Raises $20 Million in Series A Extension Financing ...
Aug 1, 2023 For more information, visit www.aulosbio.com, Twitter (@AulosBioscience) and LinkedIn. Contacts [email protected] Media inquiries: Mike Beyer, Sam Brown Inc. / 312-961 …See details»
Aulos Bioscience Appoints Aron Knickerbocker as CEO
Mar 15, 2021 BOSTON and TEL AVIV, Israel, March 15, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company that is developing highly differentiated interleukin-2 (IL …See details»
Board of Directors - Aulos Bioscience
Over the course of 10 years in that role, his organization developed and obtained regulatory approval for 11 new cancer medicines, including first-in-class medicines Ibrance® (palbociclib) …See details»
ATP and Biolojic Design Launch Aulos Bioscience to Develop
Jan 8, 2021 A link to the webcast will be available on the Aulos website at aulosbio.com. About ATP. Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in …See details»
Aulos Bioscience Announces FDA Clearance of IND ... - Business Wire
Oct 31, 2022 For more information, visit www.aulosbio.com. Contacts Contact: [email protected] Media inquiries: Mike Beyer, Sam Brown Inc. / 312-961-2502 / …See details»
Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 …
May 5, 2022 LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in …See details»
Aulos Bioscience Appoints Aron Knickerbocker as CEO - PR …
Mar 15, 2021 BOSTON and TEL AVIV, Israel, March 15, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company that is developing highly differentiated interleukin-2 (IL …See details»
Corporate Presentation | Aulos Bioscience
Aulos bioscience 700 larkspur landing circle suite 108 larkspur, ca 94939See details»
Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply ...
May 15, 2024 For more information, visit www.aulosbio.com, X (@AulosBioscience) and LinkedIn. Contact: [email protected] Media inquiries: Mike Beyer, Sam Brown Inc. / 312-961 …See details»
Aulos Bioscience Announces Presentation on First-in-Human …
Apr 27, 2022 Aulos Bioscience Announces Presentation on First-in-Human Phase 1/2 Clinical Trial of Novel IL-2 Therapeutic AU-007 at 2022 ASCO Annual MeetingSee details»
Aulos Bioscience Doses First Patient in Phase 2 Cohort ... - BioSpace
5 days ago LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class …See details»
Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase …
Dec 18, 2023 For more information, visit www.aulosbio.com, X (Twitter) at @AulosBioscience and LinkedIn. Contacts [email protected] Media inquiries: Mike Beyer, Sam Brown Inc. / 312 …See details»
Our Approach - Unlocking the power of IL-2 - Aulos Bioscience
Aulos’ lead antibody, AU-007, offers an elegantly simple solution for harnessing the immunotherapeutic power of IL-2. Created by our co-founding partner Biolojic Design, AU-007 …See details»